CALIWAY BIOPHARMACEUTICALS CO L

Company Profile

Sector

Healthcare

Industry

Biotechnology

Employees

N/A

Website

www.caliway.com.tw

Country

Taiwan

Exchange

Taiwan

Caliway Biopharmaceuticals develops drugs for aesthetic medicine and chronic inflammation. The company develops CBL-514, an investigational drug, which is in Phase 2 clinical trial for non-surgical fat reduction and Dercum's disease, as well as for cellulite treatment.

It is also developing CBA-539, which is in preclinical stage for central obesity, hyperpigmentation, and skin aging, as well as offers dietary supplements. The company was incorporated in 2012 and is based in New Taipei City, Taiwan.

Key Stats

52-Week Range

NT$75.10NT$277.00

Beta1.12

Trailing P/EN/A

Forward P/E19.09

Trailing EPS-0.19

Avg Volume

Earnings & Analyst

Next EarningsN/A

EPS Estimate2.93

Target Mean PriceNT$240.00

RecommendationNone

Recommendation MeanN/A

Recent SEC Filings

SEC filings for this ticker are not available yet.